External Validation of the Patient-Reported Villalta Scale for the Diagnosis of Postthrombotic Syndrome

Abstract

Introduction The Villalta scale is the endorsed tool to diagnose and grade the severity of postthrombotic syndrome (PTS); however, assessing presence and severity of PTS is time-consuming and relies on both the clinician and patient's assessments. The patient-reported Villalta scale version 2 (PRV2) is a visually assisted form that enables patients to self-assess presence and severity of PTS. Herein, we report on external validation of this tool.

Methods We assessed the agreement and kappa values of PRV2 to diagnose and assess severity of PTS compared with the original Villalta score in a cohort of 181 patients (196 limbs) who participated in the SAVER pilot randomized control trial. Presence of PTS was defined as PRV2 ≥5 or a Villalta score ≥5.

Results PTS prevalence was 42% using PRV2 and 33% using the Villalta scale. The corresponding kappa and percentage agreement were 0.60 (95% confidence interval [CI]: 0.49–0.71) and 81% (95% CI: 76–87), respectively. Kappa values and percentage agreements between PRV2 and Villalta scale increased with increasing severity of PTS. The sensitivity of PRV2 to detect PTS of any severity was 84% (95% CI: 73–92) with a specificity of 79% (95% CI: 71–86).

Conclusion We conclude that the PRV2 is an acceptable tool for diagnosing and grading the severity of PTS.

Keywords

deep vein thrombosis - postthrombotic syndrome - Villalta scale

Publication History

Received: 23 June 2021

Accepted: 10 January 2022

Accepted Manuscript online:
12 January 2022

Article published online:
04 March 2022

• References

• 1 Prandoni P, Kahn SR. Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol 2009; 145 (03) 286-295
• 2 Vedantham S. Valvular dysfunction and venous obstruction in the post-thrombotic syndrome. Thromb Res 2009; 123 (Suppl. 04) S62-S65
• 3 Kahn SR, Partsch H, Vedantham S, Prandoni P, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization. J Thromb Haemost 2009; 7 (05) 879-883
• 4 Kahn SR. Measurement properties of the Villalta scale to define and classify the severity of the post-thrombotic syndrome. J Thromb Haemost 2009; 7 (05) 884-888
• 5 Utne KK, Ghanima W, Foyn S, Kahn S, Sandset PM, Wik HS. Development and validation of a tool for patient reporting of symptoms and signs of the post-thrombotic syndrome. Thromb Haemost 2016; 115 (02) 361-367
• 6 Delluc A, Ghanima W, Kovacs MJ. et al. Statins for venous event reduction in patients with venous thromboembolism: a multicenter randomized controlled pilot trial assessing feasibility. J Thromb Haemost 2022; 20 (01) 126-132
• 7 Kahn SR. The post-thrombotic syndrome. Hematology (Am Soc Hematol Educ Program) 2016; 2016 (01) 413-418
• 8 Villalta S, Bagatella P, Piccioli A, Lensing A, Prandoni P. Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome. Haemostasis 1994; 24: 158a
• 9 Rodger MA, Kahn SR, Wells PS. et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179 (05) 417-426
• 10 Rodger MA, Kahn SR, Le Gal G. et al. Inter-observer reliability of measures to assess the post-thrombotic syndrome. Thromb Haemost 2008; 100 (01) 164-166
• 11 Petrie KJ, Weinman J. Patients' perceptions of their illness. Curr Dir Psychol Sci 2012; 21 (01) 60-65